Clinical Trial Update: Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD) [Phase 2]

View source ↗

Summary

Open-label extension study of PRO044 in Duchenne muscular dystrophy (Phase 2) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• PRO044

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: TERMINATED